METiS Therapeutics
PrivateLast Round
IPO
May 13, 2026
Est. Valuation
$1.55B
Total Funding Raised
$305M
Company Overview
METiS Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series D round in August 2025.
METiS Therapeutics is a biotechnology company that leverages artificial intelligence, machine learning, and quantum simulation to drive drug discovery and optimize pharmaceutical formulation processes.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
METiS Therapeutics Comparables
Compare METiS Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| XtalPi | 85% | |
| Insilico Medicine | 80% | |
| Valo Health | 76% |
For institutional investors. Book with your work email.
METiS Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | May 13, 2026 | ||||
| Series D | Aug 4, 2025 | ||||
| Series C | Jun 24, 2024 | ||||
| Series B | Apr 6, 2022 | ||||
| Series A | Dec 7, 2021 | ||||
Angel | Dec 3, 2020 |
For institutional investors. Book with your work email.
METiS Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | IPO |
| IDG Capital | IPO |
| Lake Bleu Capital | IPO |
| CCIC Capital | Series D |
| Mirae Asset | IPO |
| Hillhouse Investment | IPO |
| 招银国际金融有限公司 | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors increased 95% MoM.
- Dec 7, 2021
Raised $86M led by PICC Capital Insurance Asset Management.
For institutional investors. Book with your work email.
METiS Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about METiS Therapeutics's valuation, stock price, and market status.
Is METiS Therapeutics a public or private company?
METiS Therapeutics is a private company.
What is the current stock price of METiS Therapeutics?
METiS Therapeutics is a private company, so its shares have no public market price. Caplight tracks METiS Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is METiS Therapeutics worth (valuation)?
METiS Therapeutics's valuation is estimated at $1.5B based on funding round data.
Can I buy METiS Therapeutics stock?
METiS Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was METiS Therapeutics's last funding round?
METiS Therapeutics's most recent funding round was IPO on May 13, 2026.
Who are the main investors in METiS Therapeutics?
Key investors in METiS Therapeutics include China International Capital Corporation, PICC Capital Insurance Asset Management, Frees Fund, CICC Capital, China Life Private Equity Investment Co., Ltd..
Will METiS Therapeutics IPO soon?
No public IPO plans have been announced for METiS Therapeutics.
How can I track METiS Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in METiS Therapeutics's shares on secondary markets.